Type II (Cytotoxic) Hypersensitivity: Overview and Definition
Type II hypersensitivity, often referred to as a cytotoxic or antibody-mediated cytotoxic reaction, represents one of the four principal classes of immune reactions classified by Gell and Coombs. This type of reaction is characterized by the inappropriate immune response where Immunoglobulin G (IgG) or Immunoglobulin M (IgM) antibodies are specifically directed against antigens located on the surface of host cells or within the extracellular matrix. The term ‘cytotoxic’ stems from the primary outcome of this interaction: the targeted destruction or functional disruption of the cell bearing the recognized antigen. Unlike Type I (Immediate) hypersensitivity, which involves IgE, or Type III, which involves soluble immune complexes, Type II reactions are strictly fixed to tissue or cell surfaces, leading to highly tissue-specific damage. The antigens targeted can be either ‘intrinsic’ (normal self-antigens) or ‘extrinsic’ (a foreign substance, such as a drug hapten, that has adsorbed onto the cell surface), but in both cases, the result is the immune system’s misrecognition and attack on its own components.
Mechanism 1: Complement Activation and Cell Lysis
The classic and most rapid mechanism of Type II hypersensitivity involves the activation of the classical complement pathway. Once IgG or IgM antibodies bind to the fixed antigen on the cell surface, the Fc portions of the bound antibodies undergo a conformational change. This allows them to recruit and activate the C1 complex, initiating the classical complement cascade. The cascade leads to two primary destructive outcomes. Firstly, it generates the biologically active fragments C3a and C5a, which are potent anaphylatoxins. These fragments lead to complement-mediated inflammation by recruiting and activating inflammatory cells, particularly neutrophils, to the site of injury. These neutrophils then release proteolytic enzymes and reactive oxygen species, causing significant tissue damage, a process exemplified in anti-glomerular basement disease, also known as Goodpasture syndrome.
Secondly, the cascade culminates in the formation of C3b, which acts as a powerful opsonin, effectively marking the target cell for destruction. Macrophages and neutrophils possess receptors for C3b, facilitating the phagocytosis and ingestion of the antibody- and complement-coated cell. Most dramatically, the final stages of the complement cascade involve the assembly of the Membrane Attack Complex (MAC), a pore-like structure (comprising C5b to C9) that is inserted into the cell membrane. The MAC disrupts the phospholipid bilayer, creating a transmembrane channel that causes osmotic lysis and rapid cell death, a mechanism particularly effective against anucleated cells like red blood cells, which is the underlying cause of hemolytic transfusion reactions.
Mechanism 2: Antibody-Dependent Cellular Cytotoxicity (ADCC)
A second major cytotoxic mechanism is Antibody-Dependent Cellular Cytotoxicity (ADCC). In this process, cells are tagged with IgG or IgM antibodies that bind to the target antigen. The immune system does not rely on the complement cascade for destruction but instead employs specific effector cells. Natural Killer (NK) cells, macrophages, neutrophils, and eosinophils possess specialized surface receptors, suchably the Fc-gamma receptor III (CD16), which specifically recognize and bind to the Fc (constant) region of the antibody attached to the target cell. Once contact is established between the effector cell and the antibody-coated target cell, the effector cell is triggered to release its cytotoxic granules. These granules contain lytic enzymes such as perforin and granzymes, which are delivered into the target cell, inducing programmed cell death or apoptosis. This is a crucial mechanism in autoimmune conditions like autoimmune hemolytic anemia and immune thrombocytopenia.
Mechanism 3: Functional Disruption without Cytotoxicity
In a variation of Type II hypersensitivity, the antibody-antigen interaction does not necessarily result in cell death or inflammation but instead causes a functional disruption of the cell. This occurs when the autoantibodies are directed against cell surface receptors, effectively modulating the cell’s normal physiological signaling. This disruption can manifest in two opposing ways: blocking or stimulating the receptor. A classic example of blocking is Myasthenia Gravis, where autoantibodies bind to the acetylcholine receptors on the muscle membrane. By occupying the receptor site, the antibodies block the binding of the neurotransmitter acetylcholine, preventing muscle stimulation and leading to progressive muscle weakness. Conversely, in Graves’ disease (which is sometimes classified as a Type V hypersensitivity), autoantibodies target the thyroid-stimulating hormone (TSH) receptor. Instead of blocking the receptor, these antibodies act as an agonist, constantly stimulating the receptor. This leads to the overproduction and secretion of thyroid hormones (thyroxine), resulting in hyperthyroidism. This mechanism illustrates that the consequence of Type II reactions extends beyond mere cellular destruction to include pathological changes in cellular communication and regulation.
Clinical Examples of Type II Hypersensitivity Reactions
One of the most critical clinical examples is the **Acute Hemolytic Transfusion Reaction**, which occurs when a patient receives ABO-incompatible blood. Preformed IgM antibodies in the recipient’s plasma immediately bind to the foreign A or B antigens on the donor’s red blood cells. This robust binding rapidly activates the classical complement pathway, leading to massive, complement-mediated intravascular hemolysis (cell lysis) of the transfused cells, which can be fatal. Similarly, **Hemolytic Disease of the Newborn** (Erythroblastosis Fetalis) is a Type II reaction where an Rh-negative mother is sensitized to the Rh-D antigen from an Rh-positive fetus. Subsequent pregnancies with an Rh-positive fetus can trigger the mother’s IgG anti-D antibodies to cross the placenta, bind to the fetal red blood cells, and cause their destruction, leading to severe anemia in the fetus.
**Drug-induced Cytopenias** (like hemolytic anemia or thrombocytopenia) occur when certain drugs, such as penicillin or methyldopa, act as haptens by binding to the surface of red blood cells or platelets. This drug-protein complex becomes an extrinsic, foreign antigen, triggering the production of IgG or IgM antibodies against the complex. The subsequent antibody binding leads to the destruction of the blood cells via complement activation or ADCC, resulting in low cell counts. Furthermore, **Goodpasture Syndrome** is a classic example of an autoantibody targeting the extracellular matrix, specifically anti-collagen IV antibodies that bind to the basement membranes of the lung and kidney, causing severe damage via complement-mediated inflammation.
Finally, **Acute Rheumatic Fever (ARF)** serves as a compelling example of molecular mimicry. Following a Group A Beta-Hemolytic Streptococcus (GAS) infection, the immune system produces antibodies against streptococcal antigens. These antibodies then cross-react with structurally similar ‘self-antigens’ found in the heart (myosin) and joints (synovial proteins). The deposition of these antibodies and subsequent inflammatory response in the heart tissue causes carditis, a serious complication mediated through a Type II hypersensitivity mechanism.